| MARITIME-CVEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Maridebart cafraglutide / MariTide Cardiovascular disease, Obesity / overweight | BMI ≥27 | Ph 3 | Recruiting | 772 | Jun 2028 | — | |
| MARITIME-HFMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Maridebart cafraglutide / MariTide Heart failure, Obesity / overweight | BMI ≥30 | Ph 3 | Recruiting | 605 | Jun 2028 | — | |
| MARITIME-1Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Maridebart cafraglutide / MariTide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 243 | Jan 2027 | — | |
| MARITIME-2Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes | BMI ≥27 | Ph 3 | Active, not recruiting | 187 | Jan 2027 | — | |
| NCT06660173A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) | Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes | BMI 23-50 | Ph 2 | Active, not recruiting | 96 | Oct 2025 | — | |
| NCT05669599Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus | Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 2 | Completed | 78 | Oct 2024 | 1 | |
| MARITIME-OSA-1Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Maridebart cafraglutide / MariTide Obesity / overweight, Sleep apnea | BMI ≥27 | Ph 3 | Recruiting | 56 | Sep 2027 | — | |
| MARITIME-OSA-2Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Maridebart cafraglutide / MariTide Obesity / overweight, Sleep apnea | — | Ph 3 | Recruiting | 49 | Sep 2027 | — | |
| MARITIME-3-JEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | Maridebart cafraglutide / MariTide Obesity / overweight | BMI ≥35 | Ph 3 | Active, not recruiting | 30 | Apr 2027 | — | |
| NCT07441252A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | Maridebart cafraglutide / MariTide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI 27-40 | Ph 2 | Recruiting | 21 | Sep 2027 | — | |
| NCT07428525A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function | Maridebart cafraglutide / MariTide Healthy volunteers, Hepatic impairment | BMI ≥22 | Ph 1 | Completed | 5 | Feb 2026 | — | |
| NCT07429045A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body | Maridebart cafraglutide / MariTide Healthy volunteers, Renal impairment | BMI ≥22 | Ph 1 | Completed | 5 | Nov 2025 | — | |
| NCT07226778Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations | Maridebart cafraglutide / MariTide Obesity / overweight | BMI 25-40 | Ph 1 | Active, not recruiting | 4 | May 2026 | — | |
| NCT07313761A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations | Maridebart cafraglutide / MariTide Obesity / overweight | BMI 25-40 | Ph 1 | Active, not recruiting | 4 | Jun 2026 | — | |
| NCT04478708Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity | Maridebart cafraglutide / MariTide Obesity / overweight | BMI 30-40 | Ph 1 | Completed | 3 | Nov 2022 | 1 | results |
| NCT06976372A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity | Maridebart cafraglutide / MariTide Obesity / overweight | BMI ≥27 | Ph 1 | Completed | 3 | Dec 2024 | — | |
| NCT07523711Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity | Maridebart cafraglutide / MariTide Obesity / overweight | BMI 25-35 | Ph 1 | Recruiting | 3 | Oct 2026 | — | |
| NCT07229157Effect of Maridebart Cafraglutide on the Heart's Electrical Activity | Maridebart cafraglutide / MariTide Obesity / overweight | BMI 25-35 | Ph 1 | Active, not recruiting | 2 | Aug 2026 | — | |
| NCT07160257A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus | Maridebart cafraglutide / MariTide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 1 | Recruiting | 1 | Nov 2026 | — | |
| NCT06352892A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight | Maridebart cafraglutide / MariTide Obesity / overweight | BMI 24-40 | Ph 1 | Completed | 1 | Aug 2024 | — | |
| NCT07429032The Effect of AMG 133 on Gastric Emptying | Maridebart cafraglutide / MariTide Obesity / overweight | BMI 27-40 | Ph 1 | Completed | 1 | Nov 2025 | — | |
| NCT05056246Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants | Maridebart cafraglutide / MariTide Healthy volunteers | BMI 18-30 | Ph 1 | Completed | 1 | Apr 2022 | — | results |
| NCT07310563A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity | Maridebart cafraglutide / MariTide Obesity / overweight | BMI ≥25 | Ph 1 | Completed | 1 | May 2025 | — | |
| NCT07575399Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) | Maridebart cafraglutide / MariTide Obesity / overweight | BMI ≥25 | Ph 3 | Not yet recruiting | 0 | Jan 2028 | — | |
